FFAR2 and Alzheimer disease: To experimentally validate this mechanism, we employed CSA, a specific CypD inhibitor, to determine whether pharmacological blockade of CypD could rescue the pro-apoptotic effects induced by GPR43 knockdown in an AD model system.